trial · primary record
STAR0602
NSCLC
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 67 |
| Primary completion | 2030-06-30 |
| Primary endpoint | Phase Ib: Determine the safety of STAR0602 monotherapy in participants with TC, and safety of STAR0602 in combination with nivolumab in participants with NSCLC with or without targetable genomic alterations or mCRPC |
| Registry ID | NCT07902921 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:35:13.238Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07902921
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.